BETHLEHEM, Pa.–(EMWNews)–OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid

diagnostics, today announced that its Board of Directors has approved a

share repurchase program to acquire up to $25 million of its outstanding

common shares.

Purchases under the program will be made at the Company’s

discretion, subject to market conditions, in the open market, in

privately-negotiated transactions or otherwise, including pursuant to a

10b5-1 plan, and will be made in accordance with the regulations of the

U.S. Securities and Exchange Commission. The Company has made no

commitment to purchase any shares, and purchases may be discontinued at

any time.

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid

specimen collection devices using proprietary oral fluid technologies,

diagnostic products including immunoassays and other in vitro diagnostic

tests, and other medical devices. These products are sold in the United

States as well as internationally to various clinical laboratories,

hospitals, clinics, community-based organizations and other public

health organizations, distributors, government agencies, physicians’

offices, and commercial and industrial entities.

OraSure Technologies is the leading supplier of oral-fluid collection

devices and assays to the life insurance industry and public health

markets for the detection of antibodies to HIV. In addition, the Company

supplies oral-fluid testing solutions for drugs of abuse testing. For

more information on the Company, please go to www.orasure.com.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions